Skin Burns Drug Pipeline Analysis Report 2025

Burns, a severe form of skin and tissue injury, impact over 11 million individuals annually, making them the fourth most common trauma globally. These injuries can result in life-altering complications, including infections, fluid imbalance, and significant scarring. Current treatments, such as wound dressings and surgical procedures, often fall short in addressing pain management, healing, and aesthetic recovery, highlighting a critical need for improved therapies. Advancements in biologics, regenerative medicine, and cutting-edge drug delivery technologies are driving innovation in this field, fostering a robust pipeline of treatments to address these unmet clinical needs and improve patient outcomes.

Report Coverage

The Skin Burns Drug Pipeline Insight Report by the publisher gives comprehensive insights into skin burns therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for skin burns. The skin burns report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The skin burns pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with skin burns treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to skin burns.

Skin Burns Drug Pipeline Outlook

Skin burns are injuries to the skin caused by exposure to heat, chemicals, electricity, or radiation. These burns damage the skin layers, leading to pain, inflammation, and potential complications such as infection. Burns are categorized into first, second, and third-degree based on severity, with third-degree burns being the most severe. It requires immediate care to prevent infection and promote healing.

Skin burns treatment options include wound cleaning, dressings, and, in severe cases, skin grafts. Pain management, antibiotics, and advanced biologic therapies are increasingly utilized to enhance recovery, reduce scarring, and improve skin regeneration.

Skin Burns Epidemiology

Skin burns affect over 11 million people globally each year, with more than 90% of cases occurring in low- to middle-income countries, particularly in Africa, the Eastern Mediterranean, and South-East Asia. Severe burns, classified as =20% total body surface area (TBSA) in adults and =10% TBSA in children, result in a mortality rate of approximately 5%. Military burn casualties tend to have more severe injuries, often compounded by polytrauma and infections.

Skin Burns Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of skin burns drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies

By Route of Administration

• Oral
• Intravenous
• Others

Skin Burns Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total skin burns clinical trials.

Skin Burns Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the skin burns pipeline analysis include small molecules and monoclonal antibodies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for skin burns.

Skin Burns Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the skin burns report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in skin burns clinical trials:

• XenoTherapeutics, Inc.
• CUTISS AG
• Noveome Biotherapeutics
• Kuros Biosurgery AG
• Stratatech (a Mallinckrodt Company)

Skin Burns Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for skin burns. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of skin burns drug candidates.

Drug: Tranexamic Acid vs Thrombin JMI

The University of Kansas Medical Center is sponsoring a Phase 4 study that compares tranexamic acid and thrombin in managing split-thickness skin graft recipient sites for burns. The study aims to evaluate whether tranexamic acid is a cost-effective, non-inferior alternative to thrombin. With 62 participants, the study is expected to conclude in December 2026.

Biological: DenovoSkin(TM)

It is currently in a Phase III clinical trial and is an autologous dermo-epidermal skin substitute, for treating severe burns in adults and adolescents aged 12 and older. Sponsored by CUTISS AG, the study is intended to compare denovoSkin™ against split-thickness skin grafts to achieve wound closure and minimizing scarring. The trial, involving 70 participants, is expected to conclude by June 2028.

Drug: 4-Aminopyridine

The drug 4-Aminopyridine is being tested in a Phase 2 clinical study to accelerate healing in burn patients. Sponsored by the University of Arizona, the objective of this study is to evaluate the role of 4-AP in enhancing burn wound recovery. With around 200 enrolled patients, the study is expected to be completed by September 2028.

Reasons To Buy This Report

The Skin Burns Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for skin burns. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within skin burns pipeline insights.

Key Questions Answered in the Skin Burns - Pipeline Insight Report

• Which companies/institutions are leading the skin burns drug development?
• What is the efficacy and safety profile of skin burns pipeline drugs?
• Which company is leading the skin burns pipeline development activities?
• What is the current skin burns commercial assessment?
• What are the opportunities and challenges present in the skin burns drug pipeline landscape?
• What is the efficacy and safety profile of skin burns pipeline drugs?
• Which company is conducting major trials for skin burns drugs?
• Which companies/institutions are involved in skin burns collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in skin burns?

This product will be delivered within 3-5 business days.